-
Avelumab, sold
under the
brand name Bavencio, is a
fully human monoclonal antibody medication for the
treatment of
Merkel cell carcinoma,
urothelial carcinoma...
- was
approved for
medical use in the
United States in
September 2024.
Avelumab, sold
under the
brand name Bavencio, is a
fully human monoclonal antibody...
- non-small cell lung cancer.
Avelumab (Bavencio) is a
fully human IgG1
antibody developed by
Merck Serono and Pfizer.
Avelumab is FDA
approved for the treatment...
-
These checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab,
avelumab, atezolizumab, and durvalumab. From a
total 5,898
patients who received...
-
Retifanlimab Toripalimab PD-L1
inhibitorsTooltip Programmed death-ligand 1 AUNP12 CA-170 BMS-202 BMS-986189
Atezolizumab Avelumab Cosibelimab Durvalumab KN035...
-
results in more
progression of the
cancer than pembrolizumab,
axitinib and
avelumab. In
comparison to
pembrolizumab and axitinib, it
probably results in more...
-
Retifanlimab Toripalimab PD-L1
inhibitorsTooltip Programmed death-ligand 1 AUNP12 CA-170 BMS-202 BMS-986189
Atezolizumab Avelumab Cosibelimab Durvalumab KN035...
-
collaboration with
Pfizer to
evaluate combination of
Bempegaldesleukin with
avelumab and
talazoparib or
enzalutamide in
multiple cancers. In
March 2022 it was...
- studied.
Dostarlimab exhibits better efficacy than PD-L1 inhibitors, such as
avelumab and durvalumab, in dMMR
advanced endometrial cancers.
Efficacy of the drug...
-
Necitumumab L01FF01
Nivolumab L01FF02
Pembrolizumab L01FF03
Durvalumab L01FF04
Avelumab L01FF05
Atezolizumab L01FF06
Cemiplimab L01FF07
Dostarlimab L01FF08 Prolgolimab...
